Ceritinib (Zykadia®) added to Possible TdP Risk List

The safe use of the  CredibleMeds^® lists of QT-prolonging medications requires awareness of any changes that are made to the lists.  Therefore, we wish to inform you of the following changes.

We have evaluated the available evidence for the cancer drug, ceritinib (Zykadia®), and found substantial evidence that it prolongs the QT interval in some patients during routine use.  We did not find convincing evidence of torsades de pointes ventricular arrhthmias associated with the drug at this time.  Therefore, we have added ceritinib to the list of drugs with Possible Risk of TdP and also to the list of Drugs to Avoid for patients with congenital long QT syndrome, if feasible.  Since this drug is used to treat cancer, avoiding its use may not be possible and therefore we recommend careful monitoring of the QT interval if it is given to these patients.